The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 19, 2024
Filed:
Nov. 22, 2019
Applicants:
Zogenix International Limited, Berkshire, GB;
Karl Bozicevic, Redwood City, CA (US);
Inventors:
Bradley S. Galer, West Chester, PA (US);
Bret Megargel, San Diego, CA (US);
Assignee:
Zogenix International Limited, Berkshire, GB;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/137 (2006.01); A61K 31/04 (2006.01); A61K 31/05 (2006.01); A61K 31/36 (2006.01); A61P 25/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 31/04 (2013.01); A61K 31/05 (2013.01); A61K 31/36 (2013.01); A61P 25/08 (2018.01);
Abstract
A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT, 5-HT, 5-HTor sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg/kg/day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg/kg/day, to a maximum of 30 mg/day in a liquid oral dose.